IMC Chicago
APLS

IMC Chicago’s Apellis Pharmaceuticals APLS Stock Holding History

IMC Chicago’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.39M Buy
34,600
+20,000
+137% +$431K ﹤0.01% 2935
2025
Q4 		$367K Sell
14,600
-4,300
-23% -$101K ﹤0.01% 3680
2025
Q3 		$428K Buy
18,900
+2,200
+13% +$51.3K ﹤0.01% 3265
2025
Q2 		$289K Buy
16,700
+6,100
+58% +$113K ﹤0.01% 3123
2025
Q1 		$232K Buy
+10,600
New +$293K ﹤0.01% 3015
2023
Q4 		– Sell
-52,600
Closed -$2M – 1804
2023
Q3 		$2M Buy
+52,600
New +$2.31M ﹤0.01% 980

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

IMC Chicago's APLS Position: Q1 2026 in Review

IMC Chicago increased its Apellis Pharmaceuticals (APLS) stake by 178% in Q1 2026, buying an estimated $817K and bringing the position to 59,232 shares worth $2.38M. The position accounts for ﹤0.01% of the portfolio, ranked #2402.

IMC Chicago first reported a position in APLS in Q4 2025 and has held it in 2 quarters since. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • IMC Chicago held 59,232 shares of Apellis Pharmaceuticals worth $2.38M as of Q1 2026.
  • IMC Chicago bought 37,908 Apellis Pharmaceuticals shares in Q1 2026, an estimated $817K.
  • Apellis Pharmaceuticals made up ﹤0.01% of IMC Chicago's portfolio in Q1 2026, its #2402 holding.
  • IMC Chicago first reported a position in Apellis Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.